Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories; Warner Chilcott
• Treatments: Azimilide

Criteria

Inclusion Criteria:

• No inclusion criteria as the patient to be included is this compassionate use protocol is currently receiving azimilide therapy

Exclusion Criteria:

• Currently taking Class I or other Class III antiarrhythmic drug or other drugs that may prolong QT interval.

• Is unwilling or unable to give or understand informed consent.